Kailera Therapeutics, Inc.
public_traded
Kailera Therapeutics, Inc. is publicly traded on NASDAQ under ticker KLRA.
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. The company emphasizes innovative approaches, including injectable and oral formulations, to support chronic weight management. [2] Its lead program is a dual-action gut hormone receptor agonist that has demonstrated promising clinical results in early trials.